Form 4 for AKTX Akari Therapeutics Plc
Accepted 2025-06-20 00:00:00 ET · period of report 2025-06-17 · accession 0000950170-25-088490 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-20 | 2025-06-17 | AKTX | Gaslightwala Abizer | Pres, CEO, Dir | P - Purchase | $1.20 | +15.0K | 261.4K | +6% | +$18.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | American Depositary Shares representing Ordinary Shares | 2025-06-17 | P | A | 15,000 | $1.20 | 261,428 | D | — | — | (F1) Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. |